Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTV NASDAQ:AVXL NASDAQ:PSTX NASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$3.18+2.9%$2.53$1.47▼$17.31$77.69M2.99217,240 shs45,936 shsAVXLAnavex Life Sciences$9.51+0.3%$10.54$4.93▼$14.44$816.85M0.831.11 million shs1.78 million shsPSTXPoseida Therapeutics$9.50$9.48$2.32▼$9.67$928.85M1.631.12 million shsN/AVIRVir Biotechnology$5.51+10.2%$5.08$4.16▼$14.45$765.45M1.281.60 million shs2.66 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics-1.90%+8.80%+9.19%+56.85%-73.22%AVXLAnavex Life Sciences-1.66%-0.52%-15.36%+22.80%+57.48%PSTXPoseida Therapeutics0.00%0.00%0.00%0.00%+232.17%VIRVir Biotechnology+1.21%+12.61%-0.60%-5.30%-39.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTVArtiva Biotherapeutics3.2494 of 5 stars3.50.00.00.03.12.51.3AVXLAnavex Life Sciences3.8308 of 5 stars3.50.00.04.73.50.80.6PSTXPoseida Therapeutics0.495 of 5 stars1.00.00.04.60.00.80.0VIRVir Biotechnology3.2127 of 5 stars3.51.00.00.03.33.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTVArtiva Biotherapeutics 3.00Buy$17.00456.46% UpsideAVXLAnavex Life Sciences 3.00Buy$44.00358.57% UpsidePSTXPoseida Therapeutics 2.00Hold$9.50N/AVIRVir Biotechnology 2.90Moderate Buy$26.80399.53% UpsideCurrent Analyst Ratings BreakdownLatest ARTV, VIR, AVXL, and PSTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025VIRVir BiotechnologyEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.008/27/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.008/27/2025VIRVir BiotechnologyBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$12.00 ➝ $14.008/22/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.008/13/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.008/4/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.007/11/2025VIRVir BiotechnologyRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform7/11/2025VIRVir BiotechnologyRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy$12.006/11/2025ARTVArtiva BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$12.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTVArtiva Biotherapeutics$250K298.53N/AN/A$6.10 per share0.50AVXLAnavex Life SciencesN/AN/AN/AN/A$1.06 per shareN/APSTXPoseida Therapeutics$150.86M6.16N/AN/A$1.08 per share8.80VIRVir Biotechnology$74.21M10.04N/AN/A$6.82 per share0.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTVArtiva Biotherapeutics-$65.37MN/A0.00N/AN/AN/A-42.60%-37.76%11/11/2025 (Estimated)AVXLAnavex Life Sciences-$43M-$0.57N/AN/AN/AN/A-45.67%-40.21%N/APSTXPoseida Therapeutics-$123.43M-$0.63N/AN/AN/A-40.28%-72.26%-21.53%N/AVIRVir Biotechnology-$521.96M-$4.00N/AN/AN/A-2,895.94%-50.22%-40.78%10/30/2025 (Estimated)Latest ARTV, VIR, AVXL, and PSTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q3 2025AVXLAnavex Life Sciences-$0.13-$0.16-$0.03-$0.16N/AN/A8/6/2025Q2 2025ARTVArtiva Biotherapeutics-$0.84-$0.87-$0.03-$0.87N/AN/A8/6/2025Q2 2025VIRVir Biotechnology-$0.72-$0.80-$0.08-$0.80$2.38 million$1.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/AAVXLAnavex Life SciencesN/AN/AN/AN/AN/APSTXPoseida TherapeuticsN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTVArtiva BiotherapeuticsN/A13.8413.84AVXLAnavex Life SciencesN/A8.938.93PSTXPoseida Therapeutics0.683.203.20VIRVir BiotechnologyN/A7.017.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTVArtiva BiotherapeuticsN/AAVXLAnavex Life Sciences31.55%PSTXPoseida Therapeutics46.87%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipARTVArtiva Biotherapeutics21.40%AVXLAnavex Life Sciences11.40%PSTXPoseida Therapeutics2.90%VIRVir Biotechnology16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTVArtiva Biotherapeutics8124.43 million19.20 millionN/AAVXLAnavex Life Sciences4085.89 million76.45 millionOptionablePSTXPoseida Therapeutics26097.77 million94.94 millionOptionableVIRVir Biotechnology580138.92 million116.69 millionOptionableARTV, VIR, AVXL, and PSTX HeadlinesRecent News About These CompaniesVir Biotechnology initiated with an Outperform at Evercore ISI5 hours ago | msn.comVir Biotechnology, Inc. $VIR Shares Bought by Russell Investments Group Ltd.September 2 at 3:49 AM | marketbeat.comWalleye Capital LLC Sells 183,494 Shares of Vir Biotechnology, Inc. $VIRSeptember 1 at 4:24 AM | marketbeat.comNuveen LLC Takes $2.32 Million Position in Vir Biotechnology, Inc. $VIRSeptember 1 at 3:33 AM | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Gap Up Following Analyst UpgradeAugust 29, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Rating Increased to Buy at Bank of AmericaAugust 29, 2025 | marketbeat.comBank of America Upgrades Vir Biotechnology (NASDAQ:VIR) to BuyAugust 29, 2025 | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Shares Gap Up After Analyst UpgradeAugust 29, 2025 | americanbankingnews.comVir Biotechnology stock soars after BofA upgrade, $14 targetAugust 28, 2025 | investing.comVir Stock Soars After BofA Boosts Rating on Liver TherapyAugust 28, 2025 | finance.yahoo.comVir upgraded at BoA on potential for liver disease asset; shares surge 13%August 28, 2025 | msn.comVir Biotechnology, Inc. $VIR Shares Bought by Charles Schwab Investment Management Inc.August 28, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by BrokeragesAugust 28, 2025 | marketbeat.comMicron initiated, Eli Lilly upgraded: Wall Street's top analyst callsAugust 27, 2025 | finance.yahoo.comBofA upgrades Vir Biotechnology to Buy on underappreciated HDV opportunityAugust 27, 2025 | msn.comVir Biotechnology upgraded to Buy from Neutral at BofAAugust 27, 2025 | msn.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of "Moderate Buy" from AnalystsAugust 26, 2025 | americanbankingnews.comVanguard Group Inc. Sells 323,127 Shares of Vir Biotechnology, Inc. $VIRAugust 26, 2025 | marketbeat.comVir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceAugust 25, 2025 | businesswire.comAberdeen Group plc Acquires 330,031 Shares of Vir Biotechnology, Inc. $VIRAugust 23, 2025 | marketbeat.comVir Biotechnology, Inc. $VIR Shares Bought by Public Sector Pension Investment BoardAugust 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025New Age Warfare: Anduril Is the Hype, AeroVironment Is the BuyBy Jeffrey Neal Johnson | August 28, 2025A New AI Tailwind Could Come to Boost Taiwan Semiconductor StockBy Gabriel Osorio-Mazilli | August 5, 2025ARTV, VIR, AVXL, and PSTX Company DescriptionsArtiva Biotherapeutics NASDAQ:ARTV$3.18 +0.09 (+2.91%) Closing price 04:00 PM EasternExtended Trading$3.16 -0.02 (-0.63%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Anavex Life Sciences NASDAQ:AVXL$9.51 +0.03 (+0.32%) Closing price 04:00 PM EasternExtended Trading$9.74 +0.23 (+2.42%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Poseida Therapeutics NASDAQ:PSTXPoseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.Vir Biotechnology NASDAQ:VIR$5.51 +0.51 (+10.20%) Closing price 04:00 PM EasternExtended Trading$5.53 +0.02 (+0.29%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
